Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374934 | 0.94 | BIRC5 (0.57) | BIRC5ALDH1A1KDM4ETDP1CSNK2A1 | |
| SCHEMBL6811225 | 0.93 | BIRC5 (0.62) | BIRC5ALDH1A1ACHEKDM4EBCHE | |
| SCHEMBL14399553 | 0.88 | BIRC5 (0.60) | BIRC5ALDH1A1ACHEKDM4ETDP1 | |
| SCHEMBL7371543 | 0.87 | BIRC5 (0.62) | BIRC5ALDH1A1KDM4ECSNK2A1ATM | |
| SCHEMBL13191524 | 0.83 | CSNK2A1 (0.55) | ALDH1A1KDM4ECSNK2A1ATMSMN1; SMN2 | |
| SCHEMBL4041381 | 0.82 | KDM4E (0.59) | BIRC5ALDH1A1ACHEKDM4ETDP1 | |
| SCHEMBL12845311 | 0.81 | BIRC5 (0.66) | BIRC5ALDH1A1ACHEBCHESMN1; SMN2 | |
| SCHEMBL10537941 | 0.81 | S1PR2 (0.54) | KDM4ECSNK2A1ATM | |
| SCHEMBL8107846 | 0.80 | KDM4E (0.58) | KDM4ECSNK2A1ATM | |
| SCHEMBL2573003 | 0.79 | PTPN1 (0.49) | BIRC5ALDH1A1KDM4ETDP1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1708698-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005063239-A9 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005063239-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | BIRC5 2486/4885ALDH1A1 4302/4885ACHE 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.